US2010303828A1PendingUtilityA1

Antibodies Against Human CD39 and Use Thereof for Inhibiting T Regulatory Cells Activity

59
Assignee: INST NAT SANTE RECH MEDPriority: Jan 31, 2008Filed: Jan 30, 2009Published: Dec 2, 2010
Est. expiryJan 31, 2028(~1.5 yrs left)· nominal 20-yr term from priority
Inventors:Yves LevyJean-Francois EliaouArmand BensussanNathalie Bonnefoy-Berard
A61P 31/06C07K 2317/565A61P 31/00A61P 31/20A61P 31/14A61P 33/06A61P 35/00A61P 43/00C07K 2317/76A61K 2039/505A61P 33/02C07K 2317/24C07K 16/40C07K 16/2896Y02A50/30
59
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates to antibodies against human CD39 and use thereof for inhibiting T regulatory cells (Treg) activity. More particularly CD39 antibodies may be used for the treatment or prevention of cancers and infectious diseases.

Claims

exact text as granted — not AI-modified
1 . A method for treating or preventing a disease associated with an increased T regulatory cell (Treg) activity comprising the step of administering to a subject in need thereof a CD39 antibody. 
     
     
         2 . A method according to  claim 1  wherein said disease is selected from the group consisting of cancers and infectious diseases. 
     
     
         3 . A method according to  claim 2  wherein said disease is selected from the group consisting in lung cancer, breast cancer, ovarian cancer, melanoma, liver cancer, gastric cancer and lymphoma. 
     
     
         4 . A method according to  claim 2  wherein said disease is selected from the group consisting in infection with VIH, HBV, HCV,  Plasmodium falciparum  or  Mycobacterium tuberculosis.    
     
     
         5 . A method according to  claim 1  wherein said antibody comprises:
 a heavy chain wherein the variable domain comprises at least one CDR having a sequence selected from the group consisting of SEQ ID NO:2 for CDR-H1, SEQ ID NO:3 for CDR-H2 and SEQ ID NO:4 for CDR-H3; and/or   a light chain wherein the variable domain comprises at least one CDR having a sequence selected from the group consisting of SEQ ID NO:6 for CDR-L1, SEQ ID NO:7 for CDR-L2 and SEQ ID NO:8 for CDR-L3.   
     
     
         6 . A method according to,  claim 1  wherein said antibody comprises:
 a heavy chain variable region having the amino acid sequence set forth as SEQ ID NO:1 and   a light chain variable region having the amino acid sequence set forth as SEQ ID NO: 5.   
     
     
         7 . A pharmaceutical composition for the treatment or prevention of diseases associated with an increased T regulatory cell (Treg) activity comprising an antibody  claim 7  and a pharmaceutically acceptable carrier. 
     
     
         8 . A method according to  claim 2  wherein said antibody comprises:
 a heavy chain wherein the variable domain comprises at least one CDR having a sequence selected from the group consisting of SEQ ID NO:2 for CDR-H1, SEQ ID NO:3 for CDR-H2 and SEQ ID NO:4 for CDR-H3; and/or   a light chain wherein the variable domain comprises at least one CDR having a sequence selected from the group consisting of SEQ ID NO:6 for CDR-L1, SEQ ID NO:7 for CDR-L2 and SEQ ID NO:8 for CDR-L3.   
     
     
         9 . A method according to  claim 3  wherein said antibody comprises:
 a heavy chain wherein the variable domain comprises at least one CDR having a sequence selected from the group consisting of SEQ ID NO:2 for CDR-H1, SEQ ID NO:3 for CDR-H2 and SEQ ID NO:4 for CDR-H3; and/or   a light chain wherein the variable domain comprises at least one CDR having a sequence selected from the group consisting of SEQ ID NO:6 for CDR-L1, SEQ ID NO:7 for CDR-L2 and SEQ ID NO:8 for CDR-L3.   
     
     
         10 . A method according to  claim 4  wherein said antibody comprises:
 a heavy chain wherein the variable domain comprises at least one CDR having a sequence selected from the group consisting of SEQ ID NO:2 for CDR-H1, SEQ ID NO:3 for CDR-H2 and SEQ ID NO:4 for CDR-H3; and/or   a light chain wherein the variable domain comprises at least one CDR having a sequence selected from the group consisting of SEQ ID NO:6 for CDR-L1, SEQ ID NO:7 for CDR-L2 and SEQ ID NO:8 for CDR-L3.   
     
     
         11 . A method according to  claim 2  wherein said antibody comprises:
 a heavy chain variable region having the amino acid sequence set forth as SEQ ID NO:1 and   a light chain variable region having the amino acid sequence set forth as SEQ ID NO: 5.   
     
     
         12 . A method according to  claim 3  wherein said antibody comprises:
 a heavy chain variable region having the amino acid sequence set forth as SEQ ID NO:1 and   a light chain variable region having the amino acid sequence set forth as SEQ ID NO: 5   
     
     
         13 . A method according to  claim 4  wherein said antibody comprises:
 a heavy chain variable region having the amino acid sequence set forth as SEQ ID NO:1 and   a light chain variable region having the amino acid sequence set forth as SEQ ID NO: 5.   
     
     
         14 . A method according to  claim 5  wherein said antibody comprises:
 a heavy chain variable region having the amino acid sequence set forth as SEQ ID NO:1 and   a light chain variable region having the amino acid sequence set forth as SEQ ID NO: 5.   
     
     
         15 . A pharmaceutical composition for the treatment or prevention of diseases associated with an increased T regulatory cell (Treg) activity comprising an antibody according to  claim 2  and a pharmaceutically acceptable carrier. 
     
     
         16 . A pharmaceutical composition for the treatment or prevention of diseases associated with an increased T regulatory cell (Treg) activity comprising an antibody according to  claim 3  and a pharmaceutically acceptable carrier. 
     
     
         17 . A pharmaceutical composition for the treatment or prevention of diseases associated with an increased T regulatory cell (Treg) activity comprising an antibody according to  claim 4  and a pharmaceutically acceptable carrier. 
     
     
         18 . A pharmaceutical composition for the treatment or prevention of diseases associated with an increased T regulatory cell (Treg) activity comprising an antibody according to  claim 5  and a pharmaceutically acceptable carrier. 
     
     
         19 . A pharmaceutical composition for the treatment or prevention of diseases associated with an increased T regulatory cell (Treg) activity comprising an antibody according to  claim 6  and a pharmaceutically acceptable carrier. 
     
     
         20 . A hybridoma deposited under at Collection National de Cultures de Microorganismes under CNCM deposit number I-3889. 
     
     
         21 . An antibody produced by the hybridoma of  claim 20 . 
     
     
         22 . A humanized antibody having the same heavy and light chain CDRs as an antibody of  claim 21 . 
     
     
         23 . An antibody that comprises:
 a heavy chain wherein the variable domain comprises at least one CDR having a sequence selected from the group consisting of SEQ ID NO:2 for CDR-H1, SEQ ID NO:3 for CDR-H2 and SEQ ID NO:4 for CDR-H3; and/or   a light chain wherein the variable domain comprises at least one CDR having a sequence selected from the group consisting of SEQ ID NO:6 for CDR-L1, SEQ ID NO:7 for CDR-L2 and SEQ ID NO:8 for CDR-L3.   
     
     
         24 . An antibody that comprises:
 a heavy chain variable region having the amino acid sequence set forth as SEQ ID NO:1 and   a light chain variable region having the amino acid sequence set forth as SEQ ID NO: 5.

Join the waitlist — get patent alerts

Track US2010303828A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.